The high proportion (51%) of DCM/NDLVC patients with LVRR at 12‐month follow‐up, compared to previous reports (ranging from 35% to 52%),4, 23, 24 likely reflects the impact of recently introduced pharmacological and non‐pharmacological treatments in HFrEF patients (namely, angiotensin receptor–neprilysin inhibitors and sodium–glucose cotransporter 2 inhibitors). This evidence concerns the gene MME and familial dilated cardiomyopathy.